Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
08/21/2009
Trade Name:
Xyzal
Generic or Proper Name (*):
levocetirizine dihydrochloride
Indications Studied:
Seasonal allergic rhinitis (SAR) in children 2 years of age and older; perennial allergic rhinitis (PAR) and chronic idiopathic urticaria (CIU) for children 6 months of age and older
Therapeutic Category:
Antihistamine
Ages Studied:
6 months and older
Study #:
2
Study Type:
Safety
Study Design:
Single-Blind
No Patients:
69
No Centers:
25
No Countries:
1
BPCA(B), PREA(P):
B, P
Asian:
1
Black:
54
Other:
30
White:
157
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
28
Non-Hispanic/Non Latino:
214
-
-